Trial Profile
A Phase 1, Open-Label, Single Cohort, Four-period Sequential Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Ranolazine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 09 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 09 Jul 2012 Planned end date changed from 1 Apr 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 13 Mar 2012 New trial record